Post-earnings recap
Reported
Fri, Aug 2, 2024
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
Twist Bioscience's disappointing earnings report, particularly the significant EPS miss, led to a sharp decline in the stock price by 19%. Investors may be concerned about the company's ability to meet financial expectations in the near term. The lack of revenue data and guidance adds to the uncertainty surrounding the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.47 | N/A | -85.37% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed concerns about recent performance but maintained a focus on future opportunities. They did not provide specific guidance for the upcoming quarters.
Management acknowledged challenges in meeting financial expectations.
They emphasized a focus on long-term growth despite current setbacks.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—